SBIR Phase I: A miniaturized, low-cost, implantable wireless glucose sensor technology for Diabetes management
SBIR Phase I: A miniaturized, low-cost, implantable wireless glucose sensor technology for Diabetes management
批准号:
1621991
负责人:
Muhammad Mujeeb-U-Rahman
金额:
$22.49万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-01 至 2017-08-31
中文摘要
该项目的更广泛影响/商业潜力是开发一种新颖的实时生物医学传感平台,可以彻底改变个人健康和临床研究。在美国,慢性病(心血管疾病、糖尿病等)是导致死亡和残疾的主要原因。在美国,仅糖尿病就影响了2900多万人,每年的医疗费用高达2450亿美元。疾病管理需要一个长期可靠的身体代谢监测系统。提出的无线传感技术将通过提供低成本、微创、皮下传感间质液(ISF)成分来满足这一需求,该技术使用一种新颖的毫米大小的集成系统,利用可扩展的微电子制造技术。拟议的开发工作将允许将该技术用于医学研究(药物/疾病)和联网或数字健康中的无线传感应用。目前,糖尿病患者依赖于痛苦和离散的手指测量或昂贵(每年4000美元)和短期(7天)的经皮血糖监测装置。低成本(500美元/年)、无痛、可靠和准确的血糖监测仪将提供一种适合不同患者、临床医生和研究人员的解决方案,从而产生广泛的商业影响。拟议的项目将导致植入式葡萄糖传感器真正的“用户独立”操作,带来竞争的市场优势和创造就业机会。这个小企业创新研究第一阶段项目旨在开发一个无线单片传感平台,该平台将传感、控制、自主供电和通信结合在一个毫米大小的微芯片植入物上。极小的设备尺寸最大限度地减少了异物反应,并产生了稳定的传感器组织,与目前的设备相比,允许更长时间和更稳定的操作。该设备采用行业标准技术进行无线操作,简化了系统开发和集成。该传感器在半导体平台上制造,形成一个完全集成的系统,避免了昂贵的布线和封装。半导体技术的可扩展性增强了可制造性,降低了批量生产的单位成本,并确保了大批量生产的可用性。第一阶段旨在开发针状的集成传感器解决方案,并提供适当的插入/提取装置作为概念验证,以便进行小规模动物研究,以表征系统的功能。还建议测试使用拟议系统实现性能目标的可行性(体外MARD,比最先进的CGM设备稳定的体内操作时间更长,体内MARD的测定)。在成功的可行性阶段之后,我们将优化系统性能,并在第二阶段向FDA IDE提交商业化所需的临床试验申请。
英文摘要
The broader impact/commercial potential of this project is the development of a novel, real-time biomedical sensing platform that can revolutionize personal health and clinical research. Chronic diseases (cardiovascular, diabetes, etc.) are the leading causes of death and disability in US. Diabetes alone affects more than 29 million people in US, resulting in $245B annual health care cost. Disease management requires a long-term and reliable body metabolite monitoring system. The proposed wireless sensing technology will address this need by providing low-cost, minimally invasive, subdermal sensing of interstitial fluid (ISF) constituents using a novel mm-size integrated system utilizing scalable microelectronics fabrication technology. The proposed development effort will allow the use of this technology to wireless sensing applications in medical research (drugs/diseases) and connected or digital health. Currently, diabetes patients rely on painful and discrete fingerstick measurements or expensive ($4k/year) and short-lived (7 days) transcutaneous devices for glucose monitoring. A low-cost ($500/year), pain free, reliable and accurate glucose monitor will have a broad commercial impact by providing a solution suitable to a diverse set of patients as well as clinicians and researchers. The proposed project will result in a truly "user-independent" operation of implantable glucose sensors, rendering competitive market edge and job creation. This Small Business Innovation Research Phase I project is intended to develop a wireless monolithic sensing platform that combines sensing, control, autonomous powering, and communication on a single mm-size microchip implant. The extremely small device size minimizes foreign body response and results in a stable sensor-tissue, allowing for much longer and stable operation compared to current devices. The device utilizes wireless operation using industry standard technologies, simplifying system development and integration. The sensor is fabricated on the semiconductor platform to form a fully integrated system and avoid expensive wiring and packaging. The scalable nature of the semiconductor technology enhances manufacturability, reduces unit cost in volume production, and ensures the availability of high volume manufacturing. Phase-I seeks to develop the integrated sensor solution in a needle-shape form and provide appropriate insertion/extraction device as a proof-of-concept to allow for a small-scale animal study to characterize the functionality of the system. It is also proposed to test the feasibility of achieving performance goals (in-vitro MARD, stable in-vivo operation longer than state-of-the-art CGM devices, determination of in-vivo MARD) using the proposed system. After successful feasibility phase, we will optimize the system performance and move to FDA IDE filing for clinical trials needed for commercialization, during Phase II.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SBIR Phase I: A novel multianalyte microsensor platform for continuous wireless monitoring applications
-
批准号:2151738
-
项目类别:Standard Grant
-
资助金额:$25.6万
-
财政年份:2022
-
负责人:Muhammad Mujeeb-U-Rahman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Baryogenesis, Dark Matter and Nanohertz Gravitational Waves from a Dark
Supercooled Phase Transition
-
批准号:24ZR1429700
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:YUICHIRO NAKAI
-
依托单位:
ATLAS实验探测器Phase 2升级
-
批准号:11961141014
-
项目类别:国际(地区)合作与交流项目
-
资助金额:3350万元
-
批准年份:2019
-
负责人:刘衍文
-
依托单位:
地幔含水相Phase E的温度压力稳定区域与晶体结构研究
-
批准号:41802035
-
项目类别:青年科学基金项目
-
资助金额:12.0万元
-
批准年份:2018
-
负责人:张里
-
依托单位:
基于数字增强干涉的Phase-OTDR高灵敏度定量测量技术研究
-
批准号:61675216
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2016
-
负责人:叶青
-
依托单位:
基于Phase-type分布的多状态系统可靠性模型研究
-
批准号:71501183
-
项目类别:青年科学基金项目
-
资助金额:17.4万元
-
批准年份:2015
-
负责人:陈童
-
依托单位:
纳米(I-Phase+α-Mg)准共晶的临界半固态形成条件及生长机制
-
批准号:51201142
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2012
-
负责人:张英波
-
依托单位:
连续Phase-Type分布数据拟合方法及其应用研究
-
批准号:11101428
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:黄卓
-
依托单位:
D-Phase准晶体的电子行为各向异性的研究
-
批准号:19374069
-
项目类别:面上项目
-
资助金额:6.4万元
-
批准年份:1993
-
负责人:张殿琳
-
依托单位: